Extended #P2Y12 inhibitor monotherapy beyond 12 months after #PCI reduces bleeding and ischaemic events in #ACS patients at high risk for both types of events. #ESCCongress OPT-BIRISK trial - Extended clopidogrel monotherapy versus DAPT in high-risk patients.

#ESCCongress 2023: Carlos M T Aguiar interviewing Prof Braunwald at the ESC TV Spotlight; history of hypertrophic cardiomyopathy. Full house European Society of Cardiology Julia Grapsa Pascal Meier,MD Victoria Vilalta iCor Silvia Castelletti Cristina Conte Maria chiara meucci RTHahnMD rafavidalperez Ruben Casado Arroyo

Active screening of patients with type 2 #diabetes or chronic obstructive pulmonary disease (#COPD) more than doubles new diagnoses of CV compared with usual care. #ESCCongress RED-CVD trial - Improving early diagnosis of CVD in patients with type 2 diabetes and COPD.

A pragmatic natriuresis guided diuretic approach in patients with acute #heartfailure significantly increases 24-hour natriuresis without impacting all-cause mortality or heart failure rehospitalisation. #ESCCongress PUSH-AHF trial - Natriuresis guided therapy in acute heart

Some important messages from the 2023 ESC Guidelines for the mgmt of ACS which now jointly addresses STEMI and NSTE-ACS since, as the author group emphasizes, very early stages (presentation, dx) and later stages (eg 2ndary prev) are handled the same shorturl.at/mwL46

Follow this link to youtube youtu.be/CcsYvejTYyE to hear Eugene Braunwald @ #ESCCongress 2023, describing how he & AG Morrow discovered Hypertrophic Obstructive Cardiomyopathy, up to publication in Circulation 1959 (shorturl.at/cPQSV) #CardioTwitter European Society of Cardiology

Friends, A beautiful summary of #ESCCongress in our last #ESCsnacks episode brought to you by Victoria Delgado and Carlos M T Aguiar , hosted by Silvia Castelletti 👇 A marathon of trials and sessions, with many surprises, a lot of entertainment, #ESCGuidelines impact on practice,

‼️Hot of the press: #ESCCongress 2024 in London 🗓️30 August-2 September 2024 Important deadline: 👩🏻‍💻prepare your abstract and submit before 1st March 2024 youtu.be/4J0fCqegDSo?si… Personalising CV care is the spotlight We wait for you! European Society of Cardiology

It´s t h i s time of the year again .... The editorial team members of #ESCTVToday look back at the cardiology highlights of 2023 in the year-end episode just released: esc365.escardio.org/event/1523 European Society of Cardiology #cardiotwitter Carlos M T Aguiar Emma Svennberg Davide Capodanno FAU Erlangen-Nbg

My ESC News - Cardiology essentials every Wednesday 🤩 Direct to your inbox: bringing you ESC content, tools and opportunities to Expand your career, Support your learning and Connect you to the global cardiology community! Sign up today and be #BePartOfTheHeart❤️

Endomyocardial biopsy in fulminant myocarditis: need for early and accurate diagnosis to improve the outcome. Read more in #EHJ. doi.org/10.1093/eurhea… #myocarditis #biopsy #cardiotwitter European Society of Cardiology Journals European Society of Cardiology

Tricuspid valve disease and cardiac implantable electronic devices. Read the latest State of the Art Review in #EHJ: academic.oup.com/eurheartj/adva… #tricuspid #valve #TR #CIED #cardiotwitter European Society of Cardiology European Society of Cardiology Journals

Risks and Benefits of Sharing Patient Information on Social Media: A Digital Dilemma academic.oup.com/ehjdh/article/… Proud to be part of it European Society of Cardiology collaboration #EHJDigital European Society of Cardiology Journals Nico Bruining EiC EHJ Digital Health

My heart is broken. A true legend no longer on earth, forever in our ❤️❤️Your legacy will never be forgotten. You saved unmeasurable number of lives, brought us the unthinkable innovation in our field. One in a trillion!!! Dearest Alain RIP 😞😞😞😞💔💔💔

Congratulations. Beautiful paper!

📊Insights of the day from Carlos M T Aguiar who presents data from a recent study: In patients with cryptogenic stroke and atrial cardiopathy but without documented atrial fibrillation, anticoagulants are not superior to antiplatelet agents to prevent recurrent stroke. Watch

MINOCA = 6-8% of all myocardial infarctions Event rate following MINOCA about 10%/year: not lower than after ACS with coronary obstruction Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 on #ESCTVToday with lots of further insight watch: esc365.escardio.org/event/1149 (starting 05:30). European Society of Cardiology #Cardiotwitter

Aficamten for the treatment of symptomatic obstructive hypertrophic #cardiomyopathy - SEQUOIA-HCM study. #HeartFailure2024 #HFA_ESC

.Stephan Achenbach takes us through the different imaging techniques revealing lipomatous hypertrophy of the interatrial septum bit.ly/3KucexC Sign up for reminders so you Never Miss a Beat bit.ly/3IQ1B7G #ESCTVToday #CVD #cardiacCT #cardiology #cvimaging

I am so grateful to all European Society of Cardiology volunteers and staff covering #ESCCongress2024 on SoMe. You are truly amazing.